ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
About this study
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
- Condition
- Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
- Sponsor
- Erasmus Medical Center
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
- Age ≥ 18 years
- Able to understand the written informed and able to give informed consent
- Locally advanced or metastatic NSCLC with oncogenic driver mutation
- Treatment with TKI according to standard of care
Exclusion 1
- Unable to draw blood for study purposes
Where
1 site, 1 recruiting
Erasmus MC
Rotterdam, Netherlands
Contact
-
Anne-Marie Dingemans, MD, PhD
+31107040704 a.dingemans@erasmusmc.nl
Potential match only. Final eligibility is determined by the study team.